Zevra Therapeutics, Inc. ZVRA Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Zevra Therapeutics, Inc.’s reported figures.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s free cash flow?
- Zevra Therapeutics, Inc. (ZVRA) reported free cash flow of $6.11M in Q1 2026.
- How has Zevra Therapeutics, Inc.'s free cash flow changed year-over-year?
- Zevra Therapeutics, Inc.'s free cash flow increased by 173.4% year-over-year, from -$8.32M to $6.11M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s free cash flow?
- Over 2 years (2022 to 2024), Zevra Therapeutics, Inc.'s free cash flow has grown at a 92.4% compound annual growth rate (CAGR), from -$18.81M to -$69.67M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.